Ranibizumab is a Medicine belongs to Miscellaneous group whose information about Brand can be referenced from   Book : Martindale    Page : 2611   Edition : 37  

  ►   Brandname : Lucentis
  ►  Strength : Injection with 10 mg/ml. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 999   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Intravitreal
Reference :-   Book : Martindale    Page : 2611   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Neovascular (wet) age-related macular degeneration intravitreal injection 500 micrograms Injection Dose: Given once a month initially for 3 to 4 months.

Ref :-  Book : Martindale    Page : 2611   Edition : 37  



Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
►  Organ Affected CVS (Myocardial infarction)  

►  Side Effect : Intra-ocular inflammation, Endophthalmitis, Rhegmatogenous retinal detachment, Retinal tear, Iatrogenic traumatic cataract, Red eye, Eye pain, Vitreous floaters, Eyes irritation, Increased lachrymation, Sensation of a foreign body in the eye, Headache, Nausea, Arthralgia, Back pain, Bronchitis, Anaemia, Stroke
Ref :-   Book : Martindale    Page : 2610,2611   Edition : 37.  

►  Drug Interaction : Drug interaction of Ranibizumab is with NA

  ►    Mechanism of Drug Drug Interaction : 
Ref :-   Book :    Page :    Edition : .  


►  Contraindication : Patients with active or suspected ocular or periocular infections, or active severe intraocular inflammation
Ref :-   Book : Martindale    Page : 2611   Edition : 37.  
  ►  Mechanism of Action :   Ranibizumab is a recombinant humanised monoclonal antibody that binds to vascular endothelial growth factor (VEGF), thereby inhibiting the angiogenesis that occurs during tumour growth.
Ref :-   Book : Martindale    Page : 749,2610   Edition : 37.  

Pathway of DIETARY Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA


DIETARY Substance Interactions


​   ► This Medicine interact with :- NA



ContraIndication DIETARY Substance


​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   NA

►    Plasma Half-life :   Min value :-   NA    Max value :-   NA

►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA